search
Back to results

Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis (DigiToms)

Primary Purpose

Multiple Sclerosis

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
DigiCog (BCCAMS app)
Konectom Application
Sponsored by
Biogen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Sclerosis

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

For PwMS:

  • Expanded Disability Status Scale (EDSS) score ≤ 6.
  • Multiple Sclerosis (MS) diagnosis according to 2017 revised McDonald criteria.

For Healthy Participants:

- Gender-, age- and education-matched with Multiple Sclerosis participants.

Exclusion Criteria:

For PwMS:

  • Severe depression according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) classification or severe on-going psychiatric condition, as per evaluation by the investigator;
  • Change of Disease Modifiying Treatment (DMT) in the last 1 month;
  • Any clinically significant neurological disorders other than MS, as per evaluation by the investigator;
  • Any change of psychotropic treatment in the last 1 month;
  • Clinically significant addiction (alcohol or other drug abuse), as per evaluation by the investigator;
  • Recent acute relapse or disability worsening (less than one month);
  • Steroid course in the previous month;
  • Neuropsychological testing with the following tests in the previous year: Full BICAMS or DigiCog (BCCAMS app) battery, Fatigue Scale for Motor and Congnitive functions (FSMC), Computerized speed cognitive test (CSCT), Computerized Episodic Visual Memory Test (CEVMT), French Learning Test (FLT), Cognitive processing speed (CPS), Symbol Digit Modalities Test (SDMT);
  • Developmental learning disabilities, as per evaluation by the investigator;
  • Pregnant or breastfeeding women

For Health Participants:

  • Severe depression (according to DSM-5 classification) or severe on-going psychiatric condition, as per evaluation by the investigator;
  • Any clinically significant neurological disorders, as per evaluation by the investigator;
  • Any psychotropic therapy consumption;
  • Clinically significant addiction (alcohol or other drug abuse), as per evaluation by the investigator;
  • Clinically significant cognitive complaint(s), as per evaluation by the investigator;
  • Previous participation in other cognitive study using the same tests (Full BICAMS or DigiCog (BCCAMS app) battery, Fatigue Scale for Motor and Congnitive functions (FSMC), Computerized speed cognitive test (CSCT), Computerized Episodic Visual Memory Test (CEVMT), French Learning Test (FLT), Cognitive processing speed (CPS), Symbol Digit Modalities Test (SDMT));
  • Developmental learning disabilities, as per evaluation by the investigator;
  • Pregnant or breastfeeding women.

NOTE: Other protocol defined inclusion/ exclusion criteria may apply.

Sites / Locations

  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Healthy Participants

PwMS: Participants with MS

Arm Description

Healthy participants matched with PwMS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.

Participants with MS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.

Outcomes

Primary Outcome Measures

Raw Score of the Computerized Speed Cognitive Test (CSCT) using DigiCog (BCCAMS app)
Number of the correct answers will provide raw score of CSCT from which regression based norms will be calculated.
Raw Score of the Computerized Episodic Visual Memory Test (CEVMT) using DigiCog (BCCAMS app)
Total number of correct answers of the 3 trials will provide raw score of CEVMT from which regression based norms will be calculated.
Raw Score of the French Learning Test (FLT), using DigiCog (BCCAMS app)
Total number of correct answers for the 5 trials will provide raw score of FLT from which regression based norms will be calculated.

Secondary Outcome Measures

Sensitivity of the DigiCog (BCCAMS app) to detect CI in PwMS as compared to the Brief International Cognitive Assessment for MS (BICAMS)
CI will be defined for DigiCog (BCCAMS app) as one or more abnormal test within the MS sample for DigiCog (BCCAMS app) as well as the BICAMS. The reference will be CI defined as one or more abnormal BICAMS test.
Specificity of the DigiCog (BCCAMS app) to detect CI in PwMS as compared to the BICAMS
CI will be defined for DigiCog (BCCAMS app) as one or more abnormal test within the MS sample for DigiCog (BCCAMS app) as well as the BICAMS. The reference will be CI defined as one or more abnormal BICAMS test.
Accuracy of the DigiCog (BCCAMS app) to detect CI in PwMS as compared to the BICAMS
CI will be defined for DigiCog (BCCAMS app) as one or more abnormal test within the MS sample for DigiCog (BCCAMS app) as well as the BICAMS. The reference will be CI defined as one or more abnormal BICAMS test.
Relationship between Depressive Symptoms with BDI FAST and Cognitive Performance ((BICAMS/DigiCog)
Depressive symptoms will be estimated by BDI FAST (depressive scale) score. The BICAMS is used as the reference for the cognitive performances. The BCCAMS app is evaluated by using DigiCog scores.
Relationship Between Subjective Perception of CI with DailyCog and Cognitive Performance (BICAMS/DigiCog)
Subjective perception of CI will be estimated by Daily Cog score. The BICAMS is used as the reference for the cognitive performances.
Reliability of Konectom Digital Outcome Assessment (DOA) in HS and PwMS: Intraclass Correlation Coefficient (ICC) of the score for Cognitive Processing Speed test (CPS)
Reliability of Konectom DOA in HS and PwMS: ICC of the score for Pinching Test
Reliability of Konectom DOA HS and PwMS: ICC of the score for Drawing Test
Reliability of Konectom DOA HS and PwMS: ICC of the score for Grip Force Tests
Reliability of Konectom DOA in HS and PwMS: ICC of the score for 6-minute Walk Test (6MWT)
Reliability of Konectom DOA in HS and PwMS: ICC of the score for U-turn Test (UTT)
Reliability of Konectom DOA in HS and PwMS: ICC of the score for Static Balance test (SBT)
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: CPS Versus Symbol Digit Modalities Test (SDMT) in PwMS
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Pinching Versus 9-Hole Peg Test (9HPT) in PwMS
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Drawing Versus 9HPT in PwMS
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Grip Force Test Versus 9HPT in PwMS
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: SBT Versus Timed 25-foot Walk Test (T25FW) in PwMS
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: UTT Versus T25FW in PwMS
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: 6MWT Versus T25FW in PwMS
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Passive Mobility Versus T25FW in PwMS
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Konectom™ overall disability Versus Expanded Disability Status Scale (EDSS) and its Subscores in PwMS
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: CPS Score
Difference between PwMS and HS in the scores of CPS test during each testing condition will be evaluated.
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Pinching Test Score
Difference between PwMS and HS in the score of pinching test during each testing condition will be evaluated
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Drawing Test Score
Difference between PwMS and HS in the score of drawing test during each testing condition will be evaluated.
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Grip Force Test Score
Difference between PwMS and HS in the score of grip force test during each testing condition will be evaluated.
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: 6MWT Score
Difference between PwMS and HS in the score of 6MWT test during each testing condition will be evaluated.
DDifference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: UTT Score
Difference between PwMS and HS in the score of UTT test during each testing condition will be evaluated.
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: SBT Score
Difference between PwMS and HS in the score of SBT test during each testing condition will be evaluated.
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Mobility Behavior Score
Difference between PwMS and HS in the score of mobility behavior test during each testing condition will be evaluated.
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Mood Scale Question (MSQ)
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: CPS Score
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: Pinching Test Score
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: Drawing Test Score
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: Grip Force Test Score
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: 6MWT Score
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: UTT Score
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: SBT Score
Difference in Konectom DOA Between In-clinic Supervised Administration Versus Self-assessments in Free-living Environment in HS and PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: CPS Association with Cognitive Sub-Scores of the Fatigue Scale for Motor and Cognitive Functions (FSMC) in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: CPS Association with Cognitive/Psychological Items of the Multiple Sclerosis Impact Scale 29 (MSIS-29) in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: CPS Association with Daily Cog in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: Pinching Test Association with ABILHAND-56 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: Pinching Test Association with early MS manual ability questionnaires
Clinical Meaningfulness of Konectom DOA Against PRO: Drawing Test Association with ABILHAND-56 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: Drawing Test Association with early MS manual ability questionnaires
Clinical Meaningfulness of Konectom DOA Against PRO: Grip Force Test Association with ABILHAND-56 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: Grip Force Test Association with Early MS Manual Ability Questionnaires
Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with Multiple Sclerosis Walking Scale 12 items (MSWS-12) in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with Early MS Walking Ability-gait Questionnaires in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with Ambulation-related Items of the MSIS-29 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with PDDS in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with MSWS-12 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with Early MS Walking Ability-gait Questionnaires in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with Ambulation-related Items of the MSIS-29 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with PDDS in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with MSWS-12 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with Early MS Walking Ability-gait Questionnaires in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with Ambulation-related Items of the MSIS-29 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with PDDS in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with MSWS-12 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with Early MS Walking Ability-gait Questionnaires in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with Ambulation-related Items of the MSIS-29 in PwMS
Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with PDDS in PwMS

Full Information

First Posted
February 12, 2021
Last Updated
April 14, 2023
Sponsor
Biogen
search

1. Study Identification

Unique Protocol Identification Number
NCT04756700
Brief Title
Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis
Acronym
DigiToms
Official Title
Validation of DigiCog (BCCAMS App) and Konectom™ Tools, for Supporting Digitalized Clinical Assessment of Cognitive and Motor Functions in Patients With Multiple Sclerosis. DigiToms Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
October 12, 2020 (Actual)
Primary Completion Date
July 26, 2022 (Actual)
Study Completion Date
July 26, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Biogen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study is to establish scores of Cognitive impairment (CI) of the 3 DigiCog [Brief Computerized Cognitive Assessment for Multiple Sclerosis (BCCAMS) app] tests [Computerized Speed Cognitive Test (CSCT), Computerized Episodic Visual Memory Test (CEVMT) and the French Learning Test (FLT), a verbal memory test similar to the CVLT], using a tablet application in a sample of healthy participants matched to persons with MS (PwMS). The secondary objectives of this study are to determine the ability of the DigiCog app to detect cognitive impairment (CI) compared to the classical Brief International Cognitive Assessment for MS (BICAMS) in PwMS; to determine the relationship between depressive symptoms and cognitive performance in Multiple Sclerosis (MS) sample; to determine the relationship between subjective perception of CI and cognitive performance ; to evaluate the reliability of Konectom™ digital outcome assessments (DOAs) in healthy subjects (HS) and PwMS; to evaluate the convergent validity of Konectom™ digital outcome assessments (DOAs) against in-clinic conventional disability outcome assessments in PwMS; to evaluate differences in Konectom™ DOAs [self administered at home and in-clinic] between PwMS and HS; to evaluate the variability of Konectom™ DOAs self-administered at home in free-living environment in HS and PwMS; to compare Konectom™ DOAs between in-clinic supervised administration versus self-assessments in free-living environment in HS and PwMS; to evaluate the clinical meaningfulness of Konectom™ DOAs against Patient-Reported Outcomes (PRO) in PwMS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
158 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Healthy Participants
Arm Type
Experimental
Arm Description
Healthy participants matched with PwMS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
Arm Title
PwMS: Participants with MS
Arm Type
Experimental
Arm Description
Participants with MS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
Intervention Type
Diagnostic Test
Intervention Name(s)
DigiCog (BCCAMS app)
Intervention Description
Administered as specified in the treatment arm.
Intervention Type
Diagnostic Test
Intervention Name(s)
Konectom Application
Intervention Description
Administered as specified in the treatment arm.
Primary Outcome Measure Information:
Title
Raw Score of the Computerized Speed Cognitive Test (CSCT) using DigiCog (BCCAMS app)
Description
Number of the correct answers will provide raw score of CSCT from which regression based norms will be calculated.
Time Frame
Up to Day 28
Title
Raw Score of the Computerized Episodic Visual Memory Test (CEVMT) using DigiCog (BCCAMS app)
Description
Total number of correct answers of the 3 trials will provide raw score of CEVMT from which regression based norms will be calculated.
Time Frame
Up to Day 28
Title
Raw Score of the French Learning Test (FLT), using DigiCog (BCCAMS app)
Description
Total number of correct answers for the 5 trials will provide raw score of FLT from which regression based norms will be calculated.
Time Frame
Up to Day 28
Secondary Outcome Measure Information:
Title
Sensitivity of the DigiCog (BCCAMS app) to detect CI in PwMS as compared to the Brief International Cognitive Assessment for MS (BICAMS)
Description
CI will be defined for DigiCog (BCCAMS app) as one or more abnormal test within the MS sample for DigiCog (BCCAMS app) as well as the BICAMS. The reference will be CI defined as one or more abnormal BICAMS test.
Time Frame
Up to Day 28
Title
Specificity of the DigiCog (BCCAMS app) to detect CI in PwMS as compared to the BICAMS
Description
CI will be defined for DigiCog (BCCAMS app) as one or more abnormal test within the MS sample for DigiCog (BCCAMS app) as well as the BICAMS. The reference will be CI defined as one or more abnormal BICAMS test.
Time Frame
Up to Day 28
Title
Accuracy of the DigiCog (BCCAMS app) to detect CI in PwMS as compared to the BICAMS
Description
CI will be defined for DigiCog (BCCAMS app) as one or more abnormal test within the MS sample for DigiCog (BCCAMS app) as well as the BICAMS. The reference will be CI defined as one or more abnormal BICAMS test.
Time Frame
Up to Day 28
Title
Relationship between Depressive Symptoms with BDI FAST and Cognitive Performance ((BICAMS/DigiCog)
Description
Depressive symptoms will be estimated by BDI FAST (depressive scale) score. The BICAMS is used as the reference for the cognitive performances. The BCCAMS app is evaluated by using DigiCog scores.
Time Frame
Up to Day 28
Title
Relationship Between Subjective Perception of CI with DailyCog and Cognitive Performance (BICAMS/DigiCog)
Description
Subjective perception of CI will be estimated by Daily Cog score. The BICAMS is used as the reference for the cognitive performances.
Time Frame
Up to Day 28
Title
Reliability of Konectom Digital Outcome Assessment (DOA) in HS and PwMS: Intraclass Correlation Coefficient (ICC) of the score for Cognitive Processing Speed test (CPS)
Time Frame
Up to Day 28
Title
Reliability of Konectom DOA in HS and PwMS: ICC of the score for Pinching Test
Time Frame
Up to Day 28
Title
Reliability of Konectom DOA HS and PwMS: ICC of the score for Drawing Test
Time Frame
Up to Day 28
Title
Reliability of Konectom DOA HS and PwMS: ICC of the score for Grip Force Tests
Time Frame
Up to Day 28
Title
Reliability of Konectom DOA in HS and PwMS: ICC of the score for 6-minute Walk Test (6MWT)
Time Frame
Up to Day 28
Title
Reliability of Konectom DOA in HS and PwMS: ICC of the score for U-turn Test (UTT)
Time Frame
Up to Day 28
Title
Reliability of Konectom DOA in HS and PwMS: ICC of the score for Static Balance test (SBT)
Time Frame
Up to Day 28
Title
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: CPS Versus Symbol Digit Modalities Test (SDMT) in PwMS
Time Frame
Up to Day 28
Title
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Pinching Versus 9-Hole Peg Test (9HPT) in PwMS
Time Frame
Up to Day 28
Title
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Drawing Versus 9HPT in PwMS
Time Frame
Up to Day 28
Title
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Grip Force Test Versus 9HPT in PwMS
Time Frame
Up to Day 28
Title
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: SBT Versus Timed 25-foot Walk Test (T25FW) in PwMS
Time Frame
Up to Day 28
Title
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: UTT Versus T25FW in PwMS
Time Frame
Up to Day 28
Title
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: 6MWT Versus T25FW in PwMS
Time Frame
Up to Day 28
Title
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Passive Mobility Versus T25FW in PwMS
Time Frame
Up to Day 28
Title
Convergent Validity of Konectom DOA Against In-clinic Conventional Disability Outcome Assessment: Konectom™ overall disability Versus Expanded Disability Status Scale (EDSS) and its Subscores in PwMS
Time Frame
Up to Day 28
Title
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: CPS Score
Description
Difference between PwMS and HS in the scores of CPS test during each testing condition will be evaluated.
Time Frame
Up to Day 28
Title
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Pinching Test Score
Description
Difference between PwMS and HS in the score of pinching test during each testing condition will be evaluated
Time Frame
Up to Day 28
Title
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Drawing Test Score
Description
Difference between PwMS and HS in the score of drawing test during each testing condition will be evaluated.
Time Frame
Up to Day 28
Title
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Grip Force Test Score
Description
Difference between PwMS and HS in the score of grip force test during each testing condition will be evaluated.
Time Frame
Up to Day 28
Title
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: 6MWT Score
Description
Difference between PwMS and HS in the score of 6MWT test during each testing condition will be evaluated.
Time Frame
Up to Day 28
Title
DDifference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: UTT Score
Description
Difference between PwMS and HS in the score of UTT test during each testing condition will be evaluated.
Time Frame
Up to Day 28
Title
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: SBT Score
Description
Difference between PwMS and HS in the score of SBT test during each testing condition will be evaluated.
Time Frame
Up to Day 28
Title
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Mobility Behavior Score
Description
Difference between PwMS and HS in the score of mobility behavior test during each testing condition will be evaluated.
Time Frame
Up to Day 28
Title
Difference in Konectom DOA (Self-administered at Home and In-clinic) Between PwMS and HS: Mood Scale Question (MSQ)
Time Frame
Up to Day 28
Title
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: CPS Score
Time Frame
Up to Day 28
Title
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: Pinching Test Score
Time Frame
Up to Day 28
Title
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: Drawing Test Score
Time Frame
Up to Day 28
Title
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: Grip Force Test Score
Time Frame
Up to Day 28
Title
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: 6MWT Score
Time Frame
Up to Day 28
Title
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: UTT Score
Time Frame
Up to Day 28
Title
Variability of the Participant Performance throughout Konectom™ DOAs Self-administered at Home in Free-living Environment in HS and PwMS: SBT Score
Time Frame
Up to Day 28
Title
Difference in Konectom DOA Between In-clinic Supervised Administration Versus Self-assessments in Free-living Environment in HS and PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: CPS Association with Cognitive Sub-Scores of the Fatigue Scale for Motor and Cognitive Functions (FSMC) in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: CPS Association with Cognitive/Psychological Items of the Multiple Sclerosis Impact Scale 29 (MSIS-29) in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: CPS Association with Daily Cog in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Pinching Test Association with ABILHAND-56 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Pinching Test Association with early MS manual ability questionnaires
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Drawing Test Association with ABILHAND-56 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Drawing Test Association with early MS manual ability questionnaires
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Grip Force Test Association with ABILHAND-56 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Grip Force Test Association with Early MS Manual Ability Questionnaires
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with Multiple Sclerosis Walking Scale 12 items (MSWS-12) in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with Early MS Walking Ability-gait Questionnaires in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with Ambulation-related Items of the MSIS-29 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: SBT Association with PDDS in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with MSWS-12 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with Early MS Walking Ability-gait Questionnaires in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with Ambulation-related Items of the MSIS-29 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: UTT Association with PDDS in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with MSWS-12 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with Early MS Walking Ability-gait Questionnaires in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with Ambulation-related Items of the MSIS-29 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: 6MWT Association with PDDS in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with MSWS-12 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with Early MS Walking Ability-gait Questionnaires in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with Ambulation-related Items of the MSIS-29 in PwMS
Time Frame
Up to Day 28
Title
Clinical Meaningfulness of Konectom DOA Against PRO: Passive Mobility Association with PDDS in PwMS
Time Frame
Up to Day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: For PwMS: Expanded Disability Status Scale (EDSS) score ≤ 6. Multiple Sclerosis (MS) diagnosis according to 2017 revised McDonald criteria. For Healthy Participants: - Gender-, age- and education-matched with Multiple Sclerosis participants. Exclusion Criteria: For PwMS: Severe depression according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) classification or severe on-going psychiatric condition, as per evaluation by the investigator; Change of Disease Modifiying Treatment (DMT) in the last 1 month; Any clinically significant neurological disorders other than MS, as per evaluation by the investigator; Any change of psychotropic treatment in the last 1 month; Clinically significant addiction (alcohol or other drug abuse), as per evaluation by the investigator; Recent acute relapse or disability worsening (less than one month); Steroid course in the previous month; Neuropsychological testing with the following tests in the previous year: Full BICAMS or DigiCog (BCCAMS app) battery, Fatigue Scale for Motor and Congnitive functions (FSMC), Computerized speed cognitive test (CSCT), Computerized Episodic Visual Memory Test (CEVMT), French Learning Test (FLT), Cognitive processing speed (CPS), Symbol Digit Modalities Test (SDMT); Developmental learning disabilities, as per evaluation by the investigator; Pregnant or breastfeeding women For Health Participants: Severe depression (according to DSM-5 classification) or severe on-going psychiatric condition, as per evaluation by the investigator; Any clinically significant neurological disorders, as per evaluation by the investigator; Any psychotropic therapy consumption; Clinically significant addiction (alcohol or other drug abuse), as per evaluation by the investigator; Clinically significant cognitive complaint(s), as per evaluation by the investigator; Previous participation in other cognitive study using the same tests (Full BICAMS or DigiCog (BCCAMS app) battery, Fatigue Scale for Motor and Congnitive functions (FSMC), Computerized speed cognitive test (CSCT), Computerized Episodic Visual Memory Test (CEVMT), French Learning Test (FLT), Cognitive processing speed (CPS), Symbol Digit Modalities Test (SDMT)); Developmental learning disabilities, as per evaluation by the investigator; Pregnant or breastfeeding women. NOTE: Other protocol defined inclusion/ exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Biogen
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Bordeaux
ZIP/Postal Code
33000
Country
France

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
IPD Sharing URL
https://vivli.org/

Learn more about this trial

Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis

We'll reach out to this number within 24 hrs